Senior scientific leadership for biotech teams building complex biologics — from molecule and construct design to the next development decision.
Ribbon illustrations drawn from public protein structures (RCSB PDB 1IGT, 1MEL, 256B, 1STP). Not a model of any specific molecule.
Biotech startups · Pharma teams · Research organizations · Investors
From molecule design to a test plan you can take to any lab.
When you have data and options — but the decision still isn't obvious.
When the data is there — but the biological answer isn't.
Start with one defined question.
Each review answers one scientific question from public information, with a written deliverable.
Each review is the bounded written deliverable described on its card, from public information only. A broader question is scoped separately.
Stay current on one target.
One target, followed month to month, with a written brief each time.
Target Watch is the monthly brief described on the card, from public information only. A broader scope is agreed separately.
Bring me your program.
These projects use your own information. Your first inquiry should be nonconfidential; before you send project materials we agree on information sharing, any use of AI tools, and confidentiality terms.
How should this construct be laid out to give it the best chance of expressing and behaving?
Typical deliverable: a construct design with the reasoning behind it, the alternatives considered, and the expression risks to watch.
Discuss a constructYour molecule isn't expressing or behaving as expected. What should you check first, and what does your data point to?
Typical deliverable: an ordered list of what to check first, with the reasoning from your data and the experiments that would tell the possible causes apart.
Troubleshoot my programSeveral experiments could come next. Which one would change your decision, given what you know?
Typical deliverable: a comparison of the experiments you could run, a recommendation against the decision you face, and the result that would change it.
Plan the next testSomething larger or different? Describe it in a short summary.
Reconsider a shelved asset.
For a company that owns or controls a shelved biologic and can provide its own historical program data. Your first inquiry should be nonconfidential; before you share proprietary program details, we put appropriate confidentiality terms in place.
A re-analysis of the original decision to stop, using your own historical program data against current science and the current competitive field. The conclusion may be to revive the asset, to run one discriminating test, or to leave it shelved. It does not promise revival. You receive a written decision memo with the evidence behind it, keeping what is missing separate from what argues against the asset.
Given today's science and today's competition, was stopping right?
Individually scoped.
Discuss a shelved assetI use AI-assisted research and computational analysis to examine evidence and explore options more efficiently. I check the sources and assumptions behind recommendations, then make the scientific call myself.
When experimental work is needed, BiotecMaven can define the scientific question, design the work, help you evaluate proposals from the labs you are considering, interpret the results, troubleshoot problems and guide the next decision.
Clarify the scientific decision, constraints and evidence required.
Set the experimental or analytical plan and success criteria.
Advise on what to ask for and what a good proposal contains, and review the proposals you receive. You choose, contract with, and pay the lab directly.
Interpret results and turn them into the next good program decision.
I have helped shape therapeutic programs from the bench toward the clinic—spanning protein and antibody engineering, bispecifics and T-cell engagers, mammalian expression, developability, and preclinical strategy. My career spans Sanofi, Bristol Myers Squibb, Amunix, Genitope, and KaloBios, with contributions to Yervoy and Opdivo. Earlier, I conducted postdoctoral oncology research at Stanford University.
Every engagement is led directly by me, across biologics discovery, protein engineering, and program strategy.
Focused when you need a senior read. More involved when the scientific workstream needs continuity.
A senior assessment of a defined question, dataset, target, candidate or technical problem.
A bounded scientific engagement with a defined objective — from molecule or program strategy to analysis, diligence or experimental planning.
BiotecMaven defines the experimental plan and success criteria, evaluates proposals from the labs you consider, then interprets and troubleshoots the results and recommends the next step.
Ongoing senior scientific involvement for teams that need continuity without adding another full-time hire.
Tell me the decision you're facing. I'll let you know whether I can help and what a useful next step would be. Please send only a nonconfidential summary; we arrange confidential intake separately once we agree to work together.